Switching from GLP-1 Injections to Wegovy Pill Shows Additional Weight Loss of 4.1%
Recent research shows people who switch to the Wegovy pill from a GLP-1 injection can lose additional weight. PixelsEffect · E+/Getty People with overweight or obesity who switched from an injectable GLP-1 weight loss medication to the Wegovy (semaglutide) pill lost an average of 4.1% of their body weight over 3 months. After 3 months, about 2 in 5 participants had lost at least 5% of their body…
A new study presented at the European Association for the Study of Diabetes meeting in Milan found that people who switch from GLP-1 injections to Wegovy pills can lose an additional 4.1% of their body weight over three months. Among 194 adults with overweight or obesity, about two-fifths (40.7%) lost at least 5% of their body weight after three months.
The overall proportion of participants with obesity decreased by 21.6 percentage points, from 87.1% at the beginning of the study to 65.5% after three months. The study highlights the real-world effectiveness of oral semaglutide (Wegovy) as a weight loss treatment, though it does not prove causation. Experts suggest considering factors like treatment efficacy, side effects, and personal preferences when deciding between pills and injections.
Written by urgent.news from Healthline News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
